Vaccines worries hit GSK

GSK reported £8.89B in Q3 2026 earnings, exceeding estimates due to specialty medicine sales growth. Revenue rose 5% at constant exchange rates, while operating profit fell 16% to £2.13B. The company expects 3-5% full-year turnover growth and maintained its 17p quarterly dividend.

The FTSE 100 fell 0.30% as investors awaited the UK budget and reacted to earnings from GSK and Unilever. GSK dropped 4.3% despite beating Q3 expectations, while Unilever fell 3.38% after raising its volume growth forecast. The UK finance minister announced the scrapping of gas standing charges. Brent and WTI oil prices rose, while gold prices declined.

GSK plc's stock fell 4.6% after its Q3 2026 earnings report, despite beating EPS and sales estimates. Vaccine revenues declined, and operating profit dropped 16%. The company expects lower core EPS growth for the year. Barclays maintained a Sell rating, and the FTSE 100's decline added to the pressure, pushing GSK shares to an intraday low of 1823p.

GSK reported Q3 2026 sales of £8.89bn (+5% CER), core EPS of 54.6p (+1%), and reaffirmed FY guidance. The company completed a £2bn buyback in Q2, with net debt at £20.74bn. Oncology revenue reached £1.08bn in H1. GSK plans to increase late-stage oncology trials and has tariff relief agreements in place. Key drugs showed positive clinical results.

GSK reported a 16% drop in Q3 operating profit due to a £328m restructuring charge, despite 5% sales growth. Core profit rose 5%. Specialty Medicines led growth, while vaccines declined. The company reaffirmed 2026 guidance and increased its dividend. Net debt rose to £20.7bn.

GSK PLC reported Q3 adjusted EPS of 54.6 pence, beating estimates. Revenue rose 5% to £8.89B, driven by specialty medicines. Vaccines sales declined 2%. GSK reaffirmed 2026 guidance and 2031 sales outlook. Operating profit fell 16% due to restructuring charges. Cash flow from operations was £3.1B.